GAO to HHS: Learn from COVID mistakes in replacing drug-manufacturing program

The US Department of Health and Human Services (HHS) should apply learnings from failures at its drug-manufacturing centers during COVID-19 as it transitions to a new program, concludes a Government Accountability Office (GAO) report published yesterday. HHS, the primary federal department responsible for public health preparedness, created the Centers for Innovation in Advanced Development and…

Read the full article here

Related Articles